Ribomic Inc. (4591.T)
JPY 90.0
(1.12%)
JPY 90.0
(1.12%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.54 Billion JPY | -22.61% |
| 2022 | 4.58 Billion JPY | -7.48% |
| 2021 | 4.95 Billion JPY | -19.04% |
| 2020 | 6.11 Billion JPY | 169.71% |
| 2019 | 2.26 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.32 Billion JPY | -6.21% |
| 2023 Q4 | 3.54 Billion JPY | -6.23% |
| 2023 Q3 | 3.78 Billion JPY | -4.82% |
| 2023 Q2 | 3.97 Billion JPY | -6.41% |
| 2023 Q1 | 4.24 Billion JPY | -7.35% |
| 2023 FY | 3.54 Billion JPY | -22.61% |
| 2022 Q3 | 4.89 Billion JPY | 21.5% |
| 2022 Q2 | 4.03 Billion JPY | 0.0% |
| 2022 Q4 | 4.58 Billion JPY | -6.4% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 46.167% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -192.817% |
| GNI Group Ltd. | 62.39 Billion JPY | 94.315% |
| Linical Co., Ltd. | 18.53 Billion JPY | 80.867% |
| Trans Genic Inc. | 9.81 Billion JPY | 63.844% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 37.04% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 48.932% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 39.012% |
| AnGes, Inc. | 28.89 Billion JPY | 87.723% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -309.012% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 97.743% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -119.158% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 30.052% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 18.452% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -45.806% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -49.461% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 48.815% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -102.532% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 30.248% |
| PeptiDream Inc. | 67.12 Billion JPY | 94.716% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -73.834% |
| SanBio Company Limited | 5.04 Billion JPY | 29.72% |
| Healios K.K. | 15.15 Billion JPY | 76.593% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -188.335% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -17.615% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -140.63% |
| StemRIM | 9.08 Billion JPY | 60.933% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 48.439% |
| FunPep Company Limited | 2.49 Billion JPY | -42.395% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -35.461% |
| Stella Pharma Corporation | 3.82 Billion JPY | 7.155% |
| TMS Co., Ltd. | 3.55 Billion JPY | 0.211% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 38.618% |
| Cuorips Inc. | 6.18 Billion JPY | 42.645% |
| K Pharma,Inc. | 3.31 Billion JPY | -7.042% |
| Takara Bio Inc. | 123.2 Billion JPY | 97.121% |
| ReproCELL Incorporated | 9.05 Billion JPY | 60.815% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -30.639% |
| StemCell Institute Inc. | 6.54 Billion JPY | 45.786% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 49.244% |
| CellSeed Inc. | 2.46 Billion JPY | -43.86% |